Closings of first Partnering Agreements

San Francisco, March 31, 2024 - Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular and other diseases, announced first closings of partnering agreements for its lead asset dutogliptin.

After successful partnering negotiations in the last months Recardio completed the first partnering agreement closings with regional partners outside of its key territories US and Europe. The selected regional partners will be involved in the global pivotal Phase 3 study for Recardio’s lead therapeutic candidate, dutogliptin, which is being developed for the treatment of acute myocardial infarction (AMI), commonly known as heart attack. The partnering agreements include upfront and milestone payments prior to market authorization in the respective countries. Recardio will also safeguard commercial manufacturing for the drug.

“These partnerships with our regional partners, who are already market leaders in the respective hospital markets will contribute to the global successful launch and breakthrough of our lead assets dutogliptin in AMI.” said Dr. Roman Schenk, Recardio’s founder and Chairman of the Board.

About Recardio

Recardio Inc. is a late clinical-stage life science company focused on developing therapies for cardiovascular and other diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines critical for cardiac regeneration, resulting in healing cardiac tissue after an injury.

Recardio has received FDA and EMA clearance for a global pivotal phase III HEAL-MI clinical trial in acute myocardial infarction.  This trial is planned to initiate in 2025 and will serve as the basis to apply for market authorization in major global markets. Recardio plans to fully develop its therapeutic platform for patients with various cardiovascular diseases. The company is headquartered in San Francisco, California, with operations in both the US and Europe.

For more information, visit: www.recardio.eu or contact pr@recardio.eu